6-Methylhept-6-ene-1,5-diamine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 6-Methylhept-6-ene-1,5-diamine
• 英文别名: 6-methylhept-6-ene-1,5-diamine
• 化学式: C₈H₁₈N₂
• 分子量: 142.24
• InChiKey: MLJLPKICRPVHQB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  52
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• CHITOSAN-DERIVATIVE COMPOUNDS AND METHODS OF CONTROLLING MICROBIAL POPULATIONS
  申请人：Synedgen, Inc.

  公开号：EP3144324A1

  公开（公告）日：2017-03-22

  The present invention is directed to chitosan-derivative compounds and structures, methods of making chitosan-derivative compounds and methods for controlling, inhibiting and enhancing microbial populations in a variety of environments. The present invention is also directed to the control, inhibition and enhancement of microbial populations in animals, particularly humans. The microbial populations include bacteria, viruses and other pathogens where control of microbial populations are a necessity. The chitosan-derivative compounds of the present invention include chitosan-arginine compounds, related chitosan-L/D unnatural amino acid compounds, chitosan-acid amine compounds, chitosan-L/D natural amino acid derivative compounds, co-derivatives of the chitosan-derivative compounds, salts of the chitosan derivative compounds, and chitosan-guanidine compounds.

  本发明涉及壳聚糖衍生物化合物和结构、壳聚糖衍生物化合物的制造方法以及用于控制、抑制和增强各种环境中微生物种群的方法。本发明还用于控制、抑制和增强动物，特别是人类体内的微生物种群。微生物种群包括细菌、病毒和其他病原体，因此有必要控制微生物种群。本发明的壳聚糖衍生物化合物包括壳聚糖-精氨酸化合物、相关的壳聚糖-L/D非天然氨基酸化合物、壳聚糖-酸性胺化合物、壳聚糖-L/D天然氨基酸衍生物化合物、壳聚糖衍生物化合物的共衍生物、壳聚糖衍生物化合物的盐、壳聚糖-胍化合物。
• TARGETED POLYLYSINE DENDRIMER THERAPEUTIC AGENT
  申请人：Starpharma Pty Limited

  公开号：EP2052011B1

  公开（公告）日：2020-11-04
• THE USE OF COMPOUNDS TO INHIBIT 5alpha-REDUCTASE ENZYME ACTIVITY, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM
  申请人：Giuliani S.p.A.

  公开号：EP2373302B1

  公开（公告）日：2017-09-13
• Compounds and Methods for Treating or Preventing Bacterial Infections
  申请人：Baylor College of Medicine

  公开号：US20220267303A1

  公开（公告）日：2022-08-25

  The disclosure relates, in certain aspects, to compounds that can be used to inhibit β-lactamases, such as but not limited to OXA enzymes, such as but not limited to OXA-24, OXA-48, and/or OXA-58. In certain embodiments, these compounds can be used to inhibit activity of β-lactamases in vitro and in vivo.
• [EN] STABLE ANTI-IFNAR1 FORMULATION<br/>[FR] FORMULATION ANTI-IFNAR1 STABLE
  申请人：MEDIMMUNE LLC

  公开号：WO2017031288A1

  公开（公告）日：2017-02-23

  The present invention relates to a stable, low viscosity antibody formulation, wherein the formulation comprises a high concentration of anti- INFARl antibody. In some embodiments, the invention relates in general to a stable antibody formulation comprising about 100 mg/mL to about 200 mg/mL of an antibody or fragment thereof that specifically binds human interferon alpha 1 (INFARl); about 20 mM to about 80 mM of a lysine or a salt thereof; about 0.02% to about 0.06% of a surfactant; an uncharged excipient; and a formulation buffer. In some embodiments, the invention is directed to a container, dosage form and/or kit. In some embodiments, the invention is directed to a method of making and using the stable antibody formulation.